What conservative care can realistically achieve

For most people with hip osteoarthritis, avoiding surgery is a realistic and evidence-supported goal — at least for a substantial period. A 2026 randomised controlled trial involving 120 patients with moderate-to-severe hip OA (Kellgren–Lawrence grades 2–4) found that 62% of those assigned to conservative management had not crossed over to joint replacement at twelve months. This was a population in whom surgery would have been clinically defensible, which makes that proportion particularly meaningful.

What 'managed without surgery' actually means, however, deserves clarity. Conservative care does not reverse structural damage or restore lost cartilage; it controls pain and preserves function. The PHOENIX trial (2025, n=196) showed that structured exercise programmes can achieve clinically meaningful gains within three months — approximately 2.2 points of pain relief on a 0–10 scale (broadly the difference between pain that dominates daily life and pain that is present but manageable) and around 7 points of improvement on the WOMAC function questionnaire. These figures cross the thresholds that separate genuine real-world benefit from statistical noise.

That distinction — symptom control versus structural reversal — is where the evidence becomes more complicated. Non-surgical treatment works. Whether cartilage can regrow is a separate, and biologically harder, question, and the two are often conflated in ways that lead patients to misread what any treatment can offer.

The first-line pathway: exercise, weight loss, and education

Four major guideline bodies — OARSI, ACR, EULAR, and AAOS — reach the same first-line hierarchy independently: patient education, structured exercise, and weight management, before any pharmacology or injection therapy is considered. The breadth of that agreement reflects a genuine evidence base rather than consensus by committee default.

On exercise, the question patients most often ask is which type is best. The PHOENIX trial (2025, n=196) gives a direct answer: adding aerobic exercise to resistance training produced no additional benefit over resistance training alone — pain and function outcomes were statistically equivalent between the two formats. The practical implication is that the type of exercise is secondary to structured, consistent participation. Resistance training is well-supported, aerobic programmes are not harmful, but searching for a single optimal format misses the point.

Patient education belongs at the same tier, not as an administrative formality but as a measurable intervention. A 2022 systematic review of 20 studies found positive results in pain or function in 19 of them, and identified that education amplifies the effect of other conservative treatments delivered alongside it — making it simultaneously an independent intervention and an adherence multiplier.

Weight management completes the triad. Each kilogram of body weight lost reduces cumulative load across the hip socket with every step; even modest reductions translate to meaningfully lower joint stress across a full day's activity. That mechanical argument holds regardless of OA severity and applies whether a patient is considering exercise, injections, or monitoring alone.

Medications and injections: what is — and is not — recommended for the hip

When exercise and education alone leave pain at an unacceptable level, guideline bodies point to oral or topical NSAIDs as the appropriate next step — the most consistently supported pharmacological option across OARSI, ACR, EULAR, and AAOS for hip OA. Image-guided corticosteroid injections have a clear but limited role: they are appropriate for managing acute pain flares, not as a long-term strategy for disease control.

Two categories that patients frequently ask about are actively recommended against for hip OA specifically. Viscosupplementation — hyaluronic acid injections into the hip joint — is not recommended by OARSI, ACR, or EULAR for hip OA. This matters because these same injections retain conditional guideline support for knee OA, which means patients who have read about viscosupplementation in a knee OA context may reasonably assume the guidance applies to the hip as well. It does not; the hip-specific evidence base is different, and the recommendation reflects that gap rather than a blanket rejection of the treatment. Glucosamine supplements carry a similar position: guidelines do not support their use for hip OA, and opioid analgesics are actively recommended against.

Injection therapies — including PRP and newer intra-articular agents — sit at a later stage in the pathway, after first- and second-line measures have been tried; those options are considered in a separate section below.

Can cartilage grow back? What the biology actually shows

The short answer is no — and understanding why helps set realistic expectations for everything else in the treatment pathway.

Hyaline articular cartilage has no direct blood supply. Nutrients reach it slowly through diffusion from synovial fluid, which means the tissue lacks the basic biological infrastructure needed for meaningful self-repair. Once it is significantly degraded by OA, it cannot regenerate on its own — not through rest, not through supplements, and not through any specific exercise programme. Claims circulating online that cartilage can 'regrow naturally' through diet or targeted movement are not supported by current evidence.

Surgical techniques such as microfracture and drilling do stimulate some tissue repair, but what they produce is fibrocartilage — essentially scar tissue — rather than the hyaline cartilage that lines a healthy hip joint. Fibrocartilage is structurally weaker and biomechanically different from native hyaline cartilage, making these approaches suitable mainly for small, localised defects rather than the widespread joint surface changes seen in established OA.

PRP and stem cell injections are sometimes presented as regenerative options. In practice, their primary effect is anti-inflammatory: they may reduce pain and slow symptom progression, but they do not reliably regrow lost hyaline cartilage. That is not a reason to dismiss them — symptom relief and joint environment support are meaningful goals — but patients deserve an accurate account of what these treatments offer versus what they cannot do.

Where biologics and newer treatments fit in the pathway

Once first-line measures are no longer managing symptoms adequately, the pathway moves to biologic and injection-based adjuncts — used to reduce inflammation and support joint function, not to reverse structural damage.

A 2026 RCT combined ultrasound-guided hyaluronic acid injections, high-power laser therapy, and structured physiotherapy, and found improvements in hip function. One caveat is worth stating explicitly: because all three modalities were tested together, the benefit cannot be attributed to the HA component in isolation. Standalone viscosupplementation remains guideline-unrecommended for hip OA, as described in the medications section above; what the 2026 trial demonstrates is that a combined, supervised protocol may offer meaningful functional gains — not that HA injections alone constitute an evidence-based second-line step. The physiotherapy element, the laser component, or a genuine synergistic effect may account for most of the improvement; the study design does not separate them.

PRP occupies a similar position: a symptom-modulating adjunct that may reduce pain, not a tissue restorer. The biologic evidence base for hip OA specifically is sparser than for the knee, and some clinical guidance in this space is extrapolated from knee OA data rather than drawn from hip-specific trials.

Whether any exercise-and-adjunct pathway actually delays or prevents joint replacement remains, remarkably, the field's leading unanswered question: an international panel of 276 experts convened by OARSI in 2025 placed it first among their research priorities. When conservative and adjunct measures have been genuinely explored and symptoms remain functionally limiting, a surgical assessment becomes the appropriate next step.

When surgery enters the conversation — and how to know you're there

Conservative care is genuinely effective for most people with hip OA — but it has a ceiling, and recognising when that ceiling has been reached is as clinically important as pursuing the pathway in the first place.

A 2026 RCT comparing total hip arthroplasty against a self-directed exercise programme in patients with KL grade 2–4 hip OA found the surgical group achieved markedly greater improvements on both WOMAC and Harris Hip Score at 12 months — differences that exceeded the thresholds considered clinically meaningful. For a subset of patients, that gap is real and relevant.

Several indicators suggest the conservative ceiling may have been reached and specialist reassessment is warranted: persistent pain after three to six months of structured, supervised exercise and appropriate analgesia; progressive loss of function in ordinary daily activities; night pain that regularly disrupts sleep; or an inability to manage normal walking distances. None of these signals is a mandate for surgery — each is a prompt to revisit what has and has not been tried, and to have a detailed conversation about what the next step should be.

Surgery is not a consequence of failing at conservative care. It is an appropriate escalation for patients whose symptoms remain functionally limiting despite a genuine, structured trial of exercise, weight management, and adjunct treatment. That distinction matters both clinically and psychologically.

Specialist assessment at this stage draws on clinical history, physical examination, and imaging — with imaging treated as one input into a wider picture, not as a standalone verdict on the pathway.

1. [1] Total hip arthroplasty compared with conservative treatment with a self-directed exercise programme in moderate-to-severe hip OA: a randomized controlled trial. (2026). https://doi.org/10.1302/0301-620x.108b5.bjj-2025-0858.r2 https://doi.org/10.1302/0301-620x.108b5.bjj-2025-0858.r2
2. [2] Research priorities for physical activity and exercise management of people with knee and hip osteoarthritis — OARSI Rehabilitation Discussion Group. (2025). https://doi.org/10.1016/j.joca.2025.07.006 https://doi.org/10.1016/j.joca.2025.07.006
3. [3] Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial. (2025). https://doi.org/10.1016/s2665-9913%2824%2900373-4 https://doi.org/10.1016/s2665-9913%2824%2900373-4
4. [4] Combined ultrasound-guided hyaluronic acid injections, high-power laser therapy and physiotherapy improve hip function in osteoarthritis: A randomized controlled trial. (2026). https://doi.org/10.1002/jeo2.70685 https://doi.org/10.1002/jeo2.70685
5. [5] Effects of Patient Education on Pain and Function and Its Impact on Conservative Treatment in Elderly Patients with Hip and Knee OA: A Systematic Review. (2022). https://doi.org/10.3390/ijerph19106194 https://doi.org/10.3390/ijerph19106194
6. [6] AB0875 — Hybrid HA + chondroitin non-sulfated (HA-SC) in hip OA: clinical results. (2020). https://doi.org/10.1136/ANNRHEUMDIS-2020-EULAR.4186 https://doi.org/10.1136/ANNRHEUMDIS-2020-EULAR.4186